Answers are grounded in this paper and cite their sources.
Retrospective nested case-control study demonstrates accurate noninvasive prediction of fetal macrosomia via maternal cell-free DNA profiling, highlighting early risk assessment potential.
Background Fetal macrosomia is common occurrence in pregnancy, which is associated with several adverse prognosis both of maternal and neonatal. While, the accuracy of prediction of fetal macrosomia is poor. The aim of this study was to develop a reliable noninvasive prediction classifier of fetal macrosomia. Methods A total of 3600 samples of routine noninvasive prenatal testing (NIPT) data at 12 + 0 –27 + 6 weeks of gestation, which were subjected to low-coverage whole-genome sequencing of maternal plasma cell-free DNA (cfDNA), were collected from three independent hospitals. We identified set of genes with significant differential coverages by comparing the promoter profiling between macrosomia cases and controls. We selected genes to develop classifier for noninvasive predicting, by using support vector machine (SVM) and logistic regression models, respectively. The performance of each classifier was evaluated by area under the curve (AUC) analysis. Results According to the available follow-up results, 162 fetal macrosomia pregnancies and 648 matched controls were included. A total of 1086 genes with significantly differential promoter profiling were found between pregnancies with macrosomia and controls ( p < 0.05). With the AUC as a reference,the classifier based on SVM (C MA-A2 ) had the best performance, with an AUC of 0.8256 (95% CI: 0.7927–0.8586). Conclusions Our study provides that assessing the risk of fetal macrosomia by whole-genome promoter nucleosome profiling of maternal plasma cfDNA based on low-coverage next-generation sequencing is feasible.
No takes yet. Share an insight, caveat, or question.
Lu et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: